Related Experiment Video
Updated: Feb 1, 2026

Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids
Published on: January 6, 2023
Apigenin modulates cell survival pathways and restores olaparib sensitivity in high-grade serous ovarian cancer cells
Jenn-Jhy Tseng1, Yeun-Ting Hsieh2, Chien-Hsing Lu3
1Department of Obstetrics, Gynecology and Women's Health, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan; Department of Nursing, College of Nursing, HungKuang University, Taichung, Taiwan.
Objective:
High-grade serous ovarian cancer (HGSOC) presents significant therapeutic challenges, particularly due to acquired resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) such as olaparib. This study examines the potential of apigenin (API), a naturally occurring flavonoid, to modulate survival pathways and restore olaparib sensitivity in HGSOC cell lines.
Materials And Methods:
Four human HGSOC cell lines (TYK-nu, Kuramochi, CAOV3, and OVCAR3) and their olaparib-resistant derivatives were used. Olaparib resistance was induced by gradually exposing cells to increasing concentrations of olaparib. Cells were treated with API, and cell viability, apoptosis, and cell cycle distribution were assessed using MTT assays and flow cytometry. Western blotting was performed to analyze STAT3 and AKT phosphorylation, apoptotic markers, and cell cycle regulators, while immunofluorescence was used to evaluate STAT3 subcellular localization.
Results:
API reduced cell viability in all HGSOC cell lines in a dose-dependent manner, exhibiting differential sensitivity. It induced cell death in TYK-nu and OVCAR3, while causing G2/M phase arrest in Kuramochi and CAOV3. API selectively inhibited pSTAT3 (Y705) and pAKT (S308) without altering total protein levels or STAT3 nuclear localization. Additionally, it downregulated key cell cycle regulators, including p53, p27, p21, and p16 across all lines. Cyclin B1 levels decreased universally, while CDC2 (CDK1) downregulation was specific to Kuramochi and CAOV3, correlating with G2/M arrest. Notably, API restored olaparib sensitivity in resistant Kuramochi and CAOV3 cells by reducing pSTAT3 (Y705) levels, indicating that STAT3 modulation may be a potential mechanism for overcoming resistance.
Conclusion:
API suppresses HGSOC progression by inducing apoptosis, arresting the cell cycle, and modulating survival pathways. It also restores olaparib sensitivity in resistant cells, supporting its potential as an adjuvant therapy to enhance olaparib efficacy in combination treatments.
Insights
Apigenin (API) suppresses high-grade serous ovarian cancer (HGSOC) progression and restores sensitivity to poly (ADP-ribose) polymerase inhibitors (PARPi) like olaparib in resistant cells. This flavonoid modulates survival pathways, induces apoptosis, and arrests the cell cycle, showing promise as an adjuvant therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- High-grade serous ovarian cancer (HGSOC) is challenging due to resistance to therapies like poly (ADP-ribose) polymerase inhibitors (PARPi).
- Apigenin (API), a natural flavonoid, has potential therapeutic properties.
- Investigating API's role in overcoming PARPi resistance in HGSOC is crucial.
Purpose of the Study:
- To investigate apigenin's (API) potential to modulate survival pathways in HGSOC.
- To determine if API can restore sensitivity to olaparib in HGSOC cell lines.
- To explore API's effects on cell viability, apoptosis, and cell cycle progression.
Main Methods:
- Utilized four human HGSOC cell lines and their olaparib-resistant derivatives.
- Assessed cell viability, apoptosis, and cell cycle distribution via MTT assays and flow cytometry.
- Analyzed key protein phosphorylation (STAT3, AKT), apoptotic markers, and cell cycle regulators using Western blotting and immunofluorescence.
Main Results:
- Apigenin (API) reduced cell viability and induced apoptosis or cell cycle arrest (G2/M phase) in HGSOC cell lines.
- API selectively inhibited phosphorylated STAT3 (pSTAT3) and AKT (pAKT), key survival pathway components.
- API restored olaparib sensitivity in resistant cells, linked to reduced pSTAT3 levels, suggesting STAT3 modulation as a resistance-reversal mechanism.
Conclusions:
- Apigenin (API) effectively suppresses HGSOC progression through apoptosis induction and cell cycle arrest.
- API modulates critical survival pathways, including STAT3 and AKT signaling.
- API demonstrates potential as an adjuvant therapy to enhance olaparib efficacy in overcoming PARPi resistance in HGSOC.
More Related Videos
Related Concept Videos
Cancer Survival Analysis
Restorative Care
Graded Potential
Graded potentials fall into two categories: depolarizing and hyperpolarizing. Depolarizing graded potentials typically occur when sodium (Na+) or...
Cancer Cell Migration through Invadopodia
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...

